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Although it is clear that imatinib mesylate is highly
effective in metastatic gastrointestinal stromal tumor
(GIST), its optimal perioperative use is undefined. McAu-
liffe and colleagues now report a provocative study of a brief
preoperative imatinib therapy.1 Seventeen patients were
randomized to receive 3, 5, or 7 days of 600 mg imatinib,
underwent surgery immediately thereafter, and then
received 2 years of adjuvant imatinib therapy. Radiologic,
histologic, and surgical outcome measures were analyzed.
By the authors’ criteria, the response rate to 18FDG-PET
(18F-fluoro-2-deoxy-D-glucose positron emission tomogra-
phy) and dynamic computed tomography (CT) was
approximately 70% after transient preoperative therapy.
There was no mention of change in tumor density by CT,
which has been the basis of the Choi criteria2 developed at
their institution. Presumably it was unchanged. Pathologic
analysis of 10 preoperative biopsy samples and their mat-
ched surgical specimens revealed that apoptosis (the
primary endpoint of the trial) increased by a mean of 12%.
Early apoptosis has been shown previously in a mouse
model of GIST after treatment with imatinib.3 Because
early necrosis can be observed by TUNEL (terminal
deoxynucleotidyl transferase dUTP nick-end labeling)
staining as well, in the present study, it is uncertain whether
apoptosis is the only mechanism responsible for tumor
death. Interestingly, histologic cytoreduction was not
apparent despite the high radiologic response rate. Whether
patients without a radiologic response had evidence of
apoptosis was not stated.
One item that will be of primary practical interest to
surgeons is the fact that there was no difference in intra-
operative blood loss, even though blood flow was reduced
as measured by dynamic CT. This is surprising and
disappointing. It may just reflect patient selection, small
sample size, and the constraints of using historical controls.
The authors also conclude that compared with historical
controls who did not receive neoadjuvant imatinib, there
was no change in perioperative morbidity. However, the
complication rate was 18% in the present series, versus
44% in controls (P = .1). Similarly, postoperative com-
plications did not appear to be altered in 45 patients with
GIST treated with neoadjuvant imatinib on a Radiation
Therapy Oncology Group phase II trial.4 Larger studies
with proper controls are needed to identify whether neo-
adjuvant imatinib alters the rate of surgical complications.
Long-term outcome was assessed, although the analysis
is limited by the mixture of patients with primary (n = 13)
and metastatic (n = 6) disease. Recurrence-free survival
exceeded 90% at 1 year, consistent with the preliminary
data from the American College of Surgeons Oncology
Group intergroup Z9001 adjuvant trial and metastatic GIST
trials.
Although the current trial has primarily provided bio-
logic and radiologic correlative information regarding
neoadjuvant imatinib therapy in GIST, can the data be used
in clinical practice? Is there a rationale to treat patients
with resectable primary GIST for 1 week with neoadjuvant
imatinib if intraoperative blood loss and perioperative
morbidity are not affected? In patients with resectable
primary GIST, there is a theoretical possibility that intra-
operative tumor dissemination may be decreased by
diminished tumor blood flow. This unproven benefit must
be weighed against the rare occurrence of intraperitoneal
tumor rupture induced by imatinib therapy. As more tar-
geted drugs are developed, the other principal reason to use
nanoneoadjuvant therapy for resectable GIST could be to
select the most effective drug for adjuvant therapy in a
given patient. However, until there is a strong clinical
rationale, nanoneoadjuvant therapy for GIST may other-
wise have a short life span.
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